new logo.png
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
18 nov. 2021 08h30 HE | Aerami Therapeutics
DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases,...
new logo.png
Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors
11 nov. 2021 08h30 HE | Aerami Therapeutics
DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced...
new logo.png
Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension
24 juin 2021 08h00 HE | Aerami Therapeutics
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifyingDosing of patients in Phase 1 trial is...
new logo.png
Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium
23 juil. 2020 08h00 HE | Aerami Therapeutics
DURHAM, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”) announced today that Anne Whitaker, Chief Executive Officer, will present a corporate overview at the...
new logo.png
Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline
08 juin 2020 08h15 HE | Aerami Therapeutics
DURHAM, N.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...
new logo.png
Aerami Therapeutics Appoints Timm Crowder as Chief Operating Officer
05 févr. 2020 08h30 HE | Aerami Therapeutics
DURHAM, N.C., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced the appointment of...
new logo.png
Aerami Therapeutics to Present Clinical Data on Dance 501 Inhaled Human Insulin at the 19th Diabetes Technology Meeting
11 nov. 2019 08h00 HE | Aerami Therapeutics
DURHAM, N.C., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Aerami Therapeutics, a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced that it will...
new logo.png
Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases
25 sept. 2019 07h30 HE | Aerami Therapeutics
Aerami is exploring inhaled therapies beyond human insulin in multiple chronic conditions    Launched three new pipeline programs aimed at treatment of type 2 diabetes, hypoparathyroidism and human...
Dance_Logo.jpg
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
19 sept. 2019 08h30 HE | Dance Biopharm
Data demonstrated earlier onset of action and higher early effect of Dance 501 inhaled insulin compared to injected insulin lispro in patients with type 2 diabetes Validated smart inhaler delivers...